Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | TTR | P02766 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994720 | 0.87 | MEN1 (0.56) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL253750 | 0.85 | GPR35 (0.79) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL8744 | 0.85 | GPR35 (0.79) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL2218625 | 0.83 | GPR35 (0.76) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL2197458 | 0.83 | GPR35 (0.76) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL1503376 | 0.83 | GPR35 (0.76) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL5908864 | 0.83 | GPR35 (0.76) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL2260890 | 0.83 | GPR35 (0.76) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL1692116 | 0.83 | GPR35 (0.76) | GPR35ALDH1A1KMT2AMEN1HPGD | |
| Trinitrophenol SCHEMBL18691159 | 0.83 | GPR35 (0.76) | GPR35ALDH1A1KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4416143-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-5929094-A | NOVEL 3-((SUBSTITUTED) HETEROCYCLE),6-(SUBSTITUTED PHENYL)-1-OXASPIRO(4.4)NONANE DERIVATIVES; ANTAGONIZING THE EFFECT OF SUBSTANCE P BY ADMINISTERING TO BLOCK NEUROKININ-1 RECEPTORS; TREATING INFLAMMATION, MIGRAINE, EMESIS AND ASTHMA | MERCK & CO., INC. (US) | 1999-07-27 | — | — | US | disclosed |
| WO-1998017276-A1 | HETEROARYL SPIROETHERCYCLOALKYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0402486-A1 | METHOD OF OBTAINING 2-BROMINE-4,6-DINITROANILINE | ANDRIEVSKY, Alexandr Mikhailovich (SU) | 1990-12-19 | — | — | EP | disclosed |
| US-3984405-A | PYRIDO(3,2-B)(1,4)OXAZIN-3(4H)-ONES | E. R. SQUIBB & SONS, INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | GPR35 2394/4885ALDH1A1 163/4885KMT2A 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.